GO-CoA-Tat改善脂肪肝小鼠脂质代谢和氧化应激

目的 非酒精性脂肪性肝病(NAFLD)是目前最常见的肝病之一,既往研究提示GO-CoA-Tat在减轻小鼠体重和调节血糖方面发挥作用,本研究探讨GO-CoA-Tat对高脂饮食诱导的NAFLD小鼠脂质代谢和氧化应激的影响。方法 实验动物分为:对照组、高脂饮食(HFD)组和GO-CoA-Tat组。对照组给予标准饮食,HFD组和GO-CoA-Tat组均给予HFD。此外,GO-CoA-Tat组接受皮下注射GO-CoA-Tat。肝细胞油红Ｏ染色检测脂肪滴形成情况。相关检测试剂盒对各组小鼠血清生化指标进行检测。相关检测试剂盒检测氧化应激产物浓度变化。正态分布的计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。结果 给予HFD 8周后小鼠出现明显的肝脏脂肪变性,GO-CoA-Tat干预后脂肪变性明显缓解。GO-CoA-Tat组(5.455±0.186)食物摄入量较HFD组(7.672±0.268)明显下降(P=0.004)。GO-CoA-Tat组(1.165±0.038)小鼠肝脏重量较HFD组(1.392±0.051)明显下降(P=0.005)。GO-CoA-Tat组(74.791±3.857)小鼠肝脏TG含量与HFD组(96.891±2.708)相比明显下降(P=0.009)。GO-CoA-Tat组(1.441±0.044)血清TG浓度较HFD组(1.821±0.071)明显下降(P=0.01)。GO-CoA-Tat组(4.207±0.204)血清TC浓度较HFD组(5.897±0.151)明显下降(P=0.007)。GO-CoA-Tat组(6.820±0.296)GSH浓度较HFD组(5.073±0.331)明显升高(P=0.009)。GO-CoA-Tat组(223.1±7.188)SOD浓度较HFD组(178.1±8.234)明显升高(P=0.008)。GO-CoA-Tat组(12.381±0.481)MDA浓度较HFD组(16.621±0.521)明显下降(P=0.005)。结论 GO-CoA-Tat可改善NAFLD小鼠肝脏的脂质代谢和氧化应激,从而发挥肝脏保护作用。

GO-CoA-Tat improves lipid metabolism and oxidative stress in mice with fatty liver disease

Objective Non alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases at present. Previous studies have suggested that GO-CoA-Tat played a role in reducing body weight and regulating blood glucose in mice. This study investigated the effects of GO-CoA-Tat on lipid metabolism and oxidative stress in NAFLD mice induced by high-fat diet. Methods The experimental animals were divided into control group, high fat diet (HFD) group and GO-CoA-Tat group. The control group was given standard diet. HFD group and GO-CoA-Tat group were given HFD. In addition, GO-CoA-Tat group received subcutaneous injection of GO-CoA-Tat. The formation of fat droplets in hepatocytes was detected by oil red O staining. The serum biochemical indexes of mice in each group were detected with relevant test kits. The concentration changes of oxidative stress products were detected by relevant test kits. The measurement data of normal distribution were compared among multiple groups with one-way ANOVA, and further paired comparison was conducted with LSD-t test. Results After 8 weeks of HFD administration, the mice showed significant hepatic steatosis, meanwhile, the steatosis was significantly alleviated after GO-CoA-Tat intervention. Food intake in GO-CoA-Tat group (5.455±0.186) was significantly lower than HFD group (7.672±0.268) (P=0.004). The liver weight in GO-CoA-Tat group (1.165±0.038) was significantly lower than HFD group (1.392±0.051) (P=0.005). The content of TG in liver of mice in GO-CoA-Tat group (74.791±3.857) was significantly lower than HFD group (96.891±2.708) (P=0.009). Serum TG concentration in GO-CoA-Tat group (1.441±0.044) was significantly lower than HFD group (1.821±0.071) (P=0.01). Serum TC concentration in GO-CoA-Tat group (4.207±0.204) was significantly lower than HFD group (5.897±0.151) (P=0.007). GSH concentration in GO-CoA-Tat group (6.820±0.296) was significantly higher than HFD group (5.073±0.331) (P=0.009). SOD concentration in GO-CoA-Tat group (223.1±7.188) was significantly higher than HFD group (178.1±8.234) (P=0.008). The concentration of MDA in GO-CoA-Tat group (12.381±0.481) was significantly lower than HFD group (16.621±0.521) (P=0.005). Conclusion GO-CoA-Tat can improve lipid metabolism and oxidative stress in the liver of NAFLD mice, thereby exerting liver protective effects.